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Summary.-The characteristics of a single-cell immunofluorescence assay for
terminal deoxynucleotidyl transferase (terminal transferase, TdT) is described. The
data indicate that the single-cell immunofluorescence assay is highly efficient and
specific for the detection of cells containing TdT. Using this assay, we have examined
124 marrow orperipheral-blood samples from 104 patients with or without haemato-
logical malignancies. Results indicate that TdT+ cells from 6% to 100% were found
in the following patients: 34/40 samples from patients with ALL at the time of
diagnosis or during relapse; 2/3 patients with acute undifferentiated leukaemia; 2/3
patients with acute myelomonocytic leukaemia; 1/24 patients with acute myelo-
blastic leukaemia; 1/5 patients with chronic myelocytic leukaemia (CML) in blastic
crisis; and 2/2 patients with diffuse lymphoblastic lymphoma. In contrast less than
1% of TdT+ cells were found in 20 marrow or peripheral-blood samples from ALL
patients in complete remission; 8 patients with CML in chronic phase; 2 patients
with myeloma; 1 sample from a patient with Hodgkin's disease, peripheral-blood
samples from 7 normal donors and marrow samples from 6 patients without
haematological malignancies. TdT+ cells were also found in association with cells
with lymphoblast morphology. The TdT+ cells in marrow were shown to be
directly correlated with the percentage of morphological lymphoblasts, with a
Spearman rank coefficient of0.81, significant at a 0.001 level. In 2 longitudinal studies
of 2 ALL patients with TdT+ cells at diagnosis, the percentage TdT+ cells also
changed in parallel with the proportion of lymphoblasts. However, studies of 2 other
patients with morphologically diagnosed ALL with <1% TdT+ cells at diagnosis
also showed <1o% TdT+ cells throughout the period studied, indicating a stable
phenotype of blast cells in these patients. The single-cell immunofluorescence assay
for TdT, which requires <0 1 O/ of the cells used in a conventional biochemical assay,
is highly specific, and could provide a technically more efficient alternative for use in
clinics as well as in experimental investigations of subpopulations of leukaemic and
normal marrow cells.
SINCE THE INITIAL DISCOVERY of ter- in cells of a high proportion of patients
minal deoxynucleotidyl transferase (TdT) with ALL (McCaffrey et al., 1973; Hutton
in cells from a patient with acute lympho- & Coleman, 1976; Coleman et al., 1976).
blastic leukaemic (ALL) (McCaffrey et al., High levels of TdT were also found in
1973) the enzyme has been found to be some patients with chronic myelocytic
associated with certain types ofleukaemia, leukaemia (CML) during blast transforma-
and makes a clinicallyrelevantbiochemical tion (Bhattacharyya, 1975; McCaffrey
marker for the diagnosis and classification et al., 1975; Coleman et al., 1976; Sarin
of these patients. A number of studies et al., 1976) in some patients with acute
have indicated that the enzyme is present myelomonocytic leukaemia (AMML) (Cole-
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man et at., 1974) and in occasional patients
with acute myelogeneousleukaemia (AML)
(Srivastava et al., 1976). In addition, a
correlation wasestablishedwith membrane
markers typical for some types of leu-
kaemia (Hoffbrand et al., 1977, 1978). For
example, cells from patients in blastic
transformation ofCML that are character-
ized by high TdT levels usually display
morphologically lymphoid features and
carry markers of ALL cells. Furthermore,
patients identified by these criteria appear
to respond to therapy effective in patients
with ALL (Marks et al., 1978) suggesting
that the enzyme assay may not only
assist in the diagnosis and classification
but may also guide the management of
some patients.
The enzyme is routinely assayed bio-
chemically in crude cell extracts by meas-
uring the incorporation of deoxynucleo-
tidyl triphosphate in the presence of an
oligodeoxynucleotide primer. However,
these biochemical determinations require
a large number of cells and considerable
quantities of radioactive nucleotides.
Furthermore, the assay for TdT in crude
extracts is difficult, and Baltimore et al.
(1976) have indicated that it was necessary
to use an ion-exchange chromatographic
method for quantitation. This lengthy
procedure, together with the requirement
for large amounts of cells (108) make their
application to routinely obtained tissue
specimens difficult, and excludes analysis
on hypocellular samples and material from
patients in remission. In addition, the
biochemical assay is not suitable for corre-
lating the enzyme activity with morpho-
logically defined cell populations. This is
feasible with a single-cell immunofluores-
cence assay for TdT. Such an assay has
been described for detection of TdT+
cells in human (Bollum, 1978; Kung et al.,
1978) as well as in other species (Gregoire
et al., 1977; Sugimoto & Bollum, 1979). In
agreement with previously reported infor-
mation by Bollum (1978) and Kung et al.
(1978) we have established an immuno-
fluorescence assay for TdT and have
demonstrated its efficiency and reliability
for the determination ofTdT in individual
cells from leukaemic and non-leukaemic
samples.
MATERIALS AND METHODS
Patient material.-l18 samples of marrow
and peripheral blood were obtained from 98
patients with leukaemia and other haemato-
logical malignancies. Ten peripheral-blood
samples from normal volunteers and 6
specimens of marrow samples from
patients without haematological malignan-
cies were used as controls. Patients with
leukaemia were diagnosed morphologically as
described by Hasselback et al. (1967). The
assessment for TdT by biochemical quantita-
tion or immunofluorescence was performed on
mononuclear cells with density less than 1-077
g/mlobtainedfrombuffy-coatpreparations by
density centrifugation in lymphocyte separa-
tion medium (LSM, Litton Bionetics, Ken-
sington, Md., U.S.A.).
Preparation ofantiserum.-Terminal trans-
ferase was purified from calf thymus as pre-
viously reported (Okamura et al., 1978). The
final preparation of the enzyme was homo-
geneous as assessed by SDS polyacrylamide-
gel electrophoresis. Two protein bands with
mol. wt of 8,000 and 23,000 were identified,
that corresponded with the a and fi subunits
ofthe enzyme (Okamura et al., 1978). 100 ,ug
of this purified preparation in Freund's com-
plete adjuvant (Difco, Detroit, U.S.A.) were
injected s.c. into New Zealand rabbits. Seven
booster injections of 100 ,ug in Freund's in-
complete adjuvant were given subsequently
at 1-week intervals. The sera were monitored
for activity against TdT by microdiffusion
analysis and enzyme neutralization tests.
Preparation of F(ab)'2 fragments directed
against TdT.-Immunoglobulins (IgG) were
preparedfrom crude antiserum byammonium
sulphate fractionation and purified by DEAE
cellulose chromatography as described by
Fahey & Terry (1973). The purified IgG was
enriched for anti-TdT activity by affinity-
column chromatography. Two milligrams of
highly purified TdT were covalently linked to
2 g of Sepharose 4B (Pharmacia Fine Chemi-
cals) previously activated by cyanogen
bromide. Purified IgG was allowed to bind to
the TdT-Sepharose 4B column in the presence
of phosphate-buffered saline (PBS) (0-14mM
NaCl, 0-02M sodium phosphate, pH 7.2).
After extensive washing with PBS, the IgGTdT IN SINGLE LEUKAEMIC CELLS
bound to the column was eluted with 0-5M
NaCl containing 50mM glycine at pH 3 0, as
described by Taylor & Schimke (1974). The
IgGpreparation was then extensively dialysed
against OO1M acetate buffer (pH 4.5) and
F(ab)'2 fragments prepared by digestion with
hog pepsin (Worthington, New Jersey,
U.S.A.) at an enzyme:substrate ratio of 1-5:
100 (w/w) as described (Stanworth & Turner,
1973). The F(ab)'2 fragments were separated
from Fc fragments by passage through
Sephacryl S-200 (Pharmacia Fine Chemicals)
concentrated to 200 jig/ml using an Amicon
filter, and stored at -20°C until used.
Biochemical assay for TdT.-TdT activity
was measured biochemically as described
previously (Okamura et al., 1978). Briefly, 108
mononuclear cells from marrow or peripheral-
blood samples in a volume of 1 ml were soni-
cated and the extract centrifuged for 60 min
at 100,000 g. 50 jpI of the supernatant were
added to 50 Ful ofreaction mixture, yielding a
final concentration of 50mM Tris (pH 7.8)
4-7 jug of oligo dA12 18 (PL Biochemical,
Milwaukee, U.S.A.) lmM[3H] dGTP (sp. act.
12-7 ct/min/pmol (Amersham, Searle), 0 6mM
MnCl2, lmM dithiothreitol and 36 ,ug of
heat-activated bovine serum albumin (BSA).
The mixture was incubated at 37°C for 30 min
and the trichloroacetic-acid-insoluble counts
were measured (Okamura et al., 1978).
Activities of more than 0 05 u per 108
nucleated cells were considered positive for
TdT.
Immunofluorescence assay for TdT.-A
single-cell assay for TdT was established by
indirect fluorescence using the preparation of
rabbit anti-TdT F(ab)'2 fragments as the first
antibody. Cellular components reacting with
this antibody were visualized with FITC-
conjugated F(ab)'2 fragments of a goat anti-
rabbit F(ab)'2 preparation of IgG (Cappel
Laboratories, Cochranville, Penn., U.S.A.).
One to 10 x 104 nucleated cells in 0f2 ml of
0.9% NaCl containing 0X1% BSA were spun
on to a glass slide using a Cytocentrifuge
(Shandon Instrument, Penn., U.S.A.), fixed
with absolute methanol at 4°C for 10 min.
The slides were either processed directly or
stored for future use for up to 2 months at
-20°C. The fixed cells were incubated with
10 ,ul of pure rabbit anti-TdT F(ab)'2 frag-
ments (200jig/ml) at37°Cfor30 min, andthen
washed for 30 min in PBS containing 0-5M
NaCl. Subsequently 20 ,ul ofFITC-conjugated
goat F(ab)'2 fragments of rabbit IgG were
FIG. 1.-Immunofluorescence staining of terminal transferase positive (TdT+) cells in a sample of
marrow from a patient with ALL, fixed and stained as described in Materials and Methods.
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added for a further incubation period of
30 min at 3700. These slides were washed
extensively with large volumes of PBS con-
taining0-5MNaClandexaminedwithafluores-
cence microscope (Zeiss, Universal) that was
also equipped with a phase-contrast attach-
ment. As in the results previously reported
by Bollum (1978) and Kung et al. (1978) cells
positive for TdT showed a clear, strong,
fluorescence pattern of the nucleus as well as
parts ofthe cytoplasm (Fig. 1). The frequency
ofcells positive by fluorescence was expressed
as the percentage of the total number of
cells examined. Routinely, 200-250 cells were
assessed, andsamples were consideredpositive
if >1% displayed fluorescence.
RESULTS
Development of anti-TdT sera
Antisera directed against TdT were
raised in New Zealand rabbits using highly
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FIG. 2.-Anti-TdT activity in serum of
oculated animals as measured by enzyi
neutralization. 2 units of calf-thymus T
were incubated with a 1: 80 dilution
rabbit sera harvested at various times afi
initial immunization with TdT as antigt
After an incubation period of 30 min
370C, an equal volume of TdT enzyi
reaction mixture was added and the
maining enzyme activity measured
described in MIaterials and Methods.
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FIG. 3.-Neutralization of TdT, DNA poly-
merase I (E. coli) and RNA-dependent
DNA polymerase (Rauscher leukaemia
virus) by incubation with anti-TdT serum.
After incubation, the remaining TdT
enzyme activities were assayed as de-
scribed in Materials and Methods. The
enzyme activities of DNA polymerase I
and RNA-dependent DNA polymerase was
assayed as described by Okamura et al.
(1978) and Bernstein et al. (1977). TdT
with immune serum (0); TdT with pre-
immune serum (0); E. coli DNA poly-
merase I (A) (Okamura et al., 1978); and
Rauscher RNA-dependent DNA poly-
merase (U) (Bernstein et al., 1977).
purified TdT as antigen. The activity
increase was monitored weekly by testing
for ability of the serum to neutralize the
enzymatic activity of TdT. The results of
these studies are depicted in Figs 2 & 3.
As can be seen in Fig. 2, anti-TdT activity
was first observed 3 weeks afterimmuniza-
o tion, reaching a maximum at 5-7 weeks.
Fig. 3 shows a titration curve obtained
when increasing concentrations of anti-
serum were added to a constant amount
of TdT. 50% of the enzyme activity was
neutralized by a 1: 200 dilution of the
antiserum. No neutralizing activity was
7 detected in preimmune serum. In order to
examine the specificity of the anti-TdT,
in- 2 other DNA polymerases were exposed
mT to increasing concentrations of the same
of preparation ofantiserum. RNA-dependent
ter DNA polymerase from Rauscher leukaemia
en.
at virus and DNA polymerase I from E. coli
me remained unaffected, indicating that the
re- antiserum specific for TdT, and did
not react against other DNA polymerases.
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Specificity of the immnunoftuorescence assay
for TdT
The availability of this anti-TdT was
instrumental in the development of an
immunofluorescence assay. The regularly
observed immunofluorescence pattern is
illustrated in Fig. 1 for samples of marrow
cells from a patient with ALL. The speci-
ficity of the assay for TdT was established
by 2 different approaches: first, by correla-
ting data obtained by immunofluorescence
with conventional biochemical assessment;
second, by blocking the immunofluores-
cence through competition of the anti-
serum with a small quantity of highly
purified TdT.
Correlation betweenimmunoftuorescence and
biochemical assay
Measurements with both assays were
obtained for 3 samples of human thymus
TABLE I.-Correlation between the immuno-
fluorescence assay and biochemical assay
for TdT
Cell type
Human thymocyte
ALL Relapse
Remission
AML Relapse
T-cell lines
Molt-3
Jurkart
B-cell lines
HSC-28
HSC-58
Normal PBL
Enzyme
activity
(u/108
cells)
71-37
58-94
24-08
38-03
26-85
18-26
15-55
13-70
6-00
< 0-01
< 0-01
<0-01
< 0-01
< 0-01
< 0-01
42-11
159-05
< 0-01
<0-01
< 0-01
< 0-01
<0-01
2
3
1
2
3
4
5
6
1
2
3
1
2
3
1
2
3
Immuno-
fluores-
cence
assay
(%)
92-1
70-1
76-9
94-4
79-6
54-0
60-0
27-0
11-1
<0-5
<0-5
<0-5
<0-5
<0-5
<0-5
70-4
56-0
< 0-5
< 0-5
< 0-5
<0-5
<0-5
Samples were prepared for biochemical assay
(107-108 cells) and immunofluorescence assay
(104-105) as described in Materials and Methods.
cells, 12 marrow or peripheral-blood
specimens from leukaemic patients and
3 normal individuals, 2 ALL T-cell lines
and 2 ALL B-cell lines. Specimens from
humanthymus, from patients with ALL in
relapse phase, and from T-cell lines were
found positive. The biochemically assessed
activities ranged from 6-0 to 159-05 u/108
nucleated cells. The frequency of cells
positive for TdT by immunofluorescence
were found to range from 11 1 to 94%.
However, specimens from 3 normal indi-
viduals, from 3 ALL patients in complete
remission, from 3 patients with AML and
from 2 ALL B-cell lines, contained no
detectable enzyme activity ( < 0 01 u/I08
nucleated cells). None of these samples
displayed more than 0.5% TdT+ cells
when assessed by immunofluorescence.
Independent examination of all samples
by both assays yielded consistent results;
only samples that contained TdT when
measured biochemically were found to be
positive for TdT by immunofluorescence,
whilst all samples without the enzyme
activity were negative by immunofluores-
cence.
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FIG. 4.-Percentage of TdT+ cells and TdT
enzyme activity in marrow cells from an
ALL patient containing TdT mixed with
different proportions of marrow cells from
a patient without haematological malig-
nancy. Marrow cells from a patient with
ALL containing 95% TdT+ cells and 38 u
ofTdT.
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In addition to these measurements,
obtained for samples from different indi-
viduals with varying activity, for one
patient the proportion of TdT+ cells was
altered by mixing known quantities of
TdT- cells from the marrow of a patient
with anaemia. The original sample from
the ALL patient contained 38 u/108
nucleated cells, and 95% of all cells
stained positive by immunofluorescence.
Fig. 4 indicates a linear correlation be-
tween the percentage of immunofluores-
cent cells and the proportion generated in
the mixture. Furthermore these deter-
minations correlated with the amount of
TdT measured biochemically.
Elimination ofimmunofiuorescence by com-
petition with TdT
To obtain further evidence for speci-
ficity we have examined the question
whether or not the fluorescence staining
of these ALL cells could be eliminated by
preincubation of the antiserum with a
small quantity of highly purified TdT.
Before their use as first antibody in the
immunofluorescence assay, 2 Htg of a
preparation of F(ab)'2, fragments directed
against TdT were incubated with 3 ,ug of
highly purified TdT. In control slides 5500
of the ALL cells from the patient stained
positive for TdT. No fluorescence was seen
after preincubation of the antiserum with
highly purified TdT.
TdT analysis by immunoftuorescence on
cells from patients with and without
haematological malignancies
Samples from 98 individuals with and
without haematological malignancies were
examined for TdT by immunofluorescence.
The results are listed in Table II. Thirty-
four of the 40 samples from patients with
ALL at the time of diagnosis or during
relapse contained TdT+ cells, whereas
none of the 20 samples examined during
clinical remission were positive. Three of
the patients, negative for TdT during
remission, were re-examined at the time of
relapse and found positive. Two further
patients, negative during remission, re-
TABLE II. TdT identified in haemato-
logical malignancies by immunofluores-
cence
Cell type
Normal thymocyte
Normal blood
lymphocyte
Control marrows*
ALL Relapse
Remission
Acute undifferentiated
leukaemia Relapse
AMML Relapse
AML Relapse phase
CML Chronic phase
Blast crisis
Alyeloma
Lymphoma
Diffuse lymphoblastic
lymphoma
Hodgkin's disease
No. of
samples
3
7
6
40
20
3
3
24
8
5
TdT+
3
0
0
34
0
2
2
1
0
1
0
0/
,o
100
0
0
85
0
75
67
4
0
20
0
1) 2 100
1 0 0
* One sample from a normal donor in a marrow
transplant, one patient with Ewing's sarcoma, one
with carcinoma of the ovary, and 3 with anaemia.
mained negative at the time of relapse. In
contrast to these results on patients with
ALL, only one patient with AML in
relapse was found positive for TdT.
Examinations of samples from patients
with a variety of other subtypes of leu-
kaemia yielded TdT+ cells in 2/3 patients
with acute undifferentiated leukaemia, 1/2
with AMML, and 1/5 with CML in blast
crisis. Eight patients with CML during
the chronic phase, 2 with myeloma and 1
with Hodgkin's lymphoma did not contain
TdT+ cells. Two patients with diffuse
lymphoblastic lymphoma displayed high
percentages of TdT+ cells.
Correlation between TdT+ cells and
lymphoblasts in patients with ALL
The high proportion of patients with
ALL positive for TdT facilitated studies
designed to establish the relationship
between TdT+ cells and morphologically
identifiable cell populations. Mononuclear
cells from 20 samples were prepared for
immunofluorescence analysis and stained
by Wright stain for morphological assess-
ment. Both types of specimens were
assessed by independent examiners. TheTdT IN SINGLE LEUKAEMIC CELLS
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FiG. 5.-Correlation between the proportion
of cells TdT+ by immunofluorescence and
the % of morphologically identified
lymphoblasts (r, =0 81, P < 0 001).
results are summarized in Fig. 5. Good
agreement was found between the propor-
tion of TdT+ cells and the percent of
lymphoblasts in each sample. The Spear-
man rank correlation coefficient (rs) of
0S81 was highly significant (P<0.001).
This correlation wasalsomaintainedduring
longitudinal assessment of 2 patients with
ALL positive for TdT at the time of
diagnosis. The results in Fig. 6 show the
proportion ofTdT+ cells for each sample in
comparison to the percentage of lympho-
blasts. As can be seen, the proportion of
TdT+ cells in the marrows ofboth patients
(J.C. and L.L.) reflects the proportion of
lymphoblasts. Two other patients (S.W.
and S.B.) who did not contain TdT+ cells
at the time ofpresentation did not display
any TdT+ cells throughout the investiga-
tions.
DISCUSSION
The characteristic features of a single-
cell immunofluorescence assay for terminal
deoxynucleotidyl transferase are pre-
sented. Our data demonstrate the immu-
nofluorescence assay as a sensitive, effi-
cient, and reproducible method for the
detection of individual cells containing
TdT. As the analysis can be performed
tIC
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FIG. 6.-Longitudinal studies of % TdT+
cells and % lymphoblasts from 4 patients
with ALL. Two patients with ALL had
TdT activity at diagnosis (J.C. and L.L.)
and 2 patients were negative (S.W. and
S.B.).
on a small number of cells ( < 0. 1% ofthat
required for a biochemical assay of the
enzyme) it is particularly useful for rapid
assessment ofclinicalspecimensandstudies
of subpopulations of leukaemic and non-
leukaemic marrow cells. In addition, it
permits the examination ofindividual cells
and provides an opportunity to correlate
TdT activity with their morphology.
Using this assay the distribution of
TdT+ cells was examined in 118 marrow
and peripheral-blood samples from 98
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patients with various types of leukaemia,
and 10 normal individuals, as well as 3
samples from human thymus. The data
also confirmed the earlier results of bio-
chemical examination (Greenwood et al.,
1977; Hoffbrand et al., 1977, 1978) and
demonstrated TdT+ cells in the majority
of samples obtained from patients with
ALL at presentation or during relapse.
Samples from patients in remission contain
<1% TdT+ cells. In contrast to ALL
patients, AML patients with one exception
were TdT-.
TdT+ cells were found in association
with cells characterized by morphological
features of lymphoblasts. A comparison
of the proportion of TdT+ cells with the
percentage oflymphoblasts in 20 indepen-
dent samples yielded a Spearman rank
coefficient of 0-81, indicating a significant
correlation (P < 0001). Longitudinal
studies of 2 ALL patients with TdT+ cells
at the time of presentation also indicated
that the proportion of TDT+ cells in their
marrow changed in parallel with the per-
centage ofmorphologically identified lym-
phoblasts. Two patients with morpho-
logical features typical of ALL were nega-
tive for TdT at the time of diagnosis and
remained negative during further follow-
up, indicating a stable phenotype of blast
cells. These data demonstrate that the
presence of TdT is typical of blasts of
some patients and not ofothers, indicating
patient heterogeneity.
At present the biological role of TdT in
cells from patients with leukaemia is not
understood. Although associated with
certain types and stages ofthe disease, the
question remains unanswered whether or
not the enzyme represents a marker
related to certain types of leukaemia or
whether TdT activity is expressed by cells
of early lymphoid differentiation. It is
hoped that a combined approach, using
the single-cell immunofluorescence assay
on populations ofleukaemic cells and nor-
mal haemopoietic progenitors selected by
growth in specific culture conditions, may
lead to further understanding of this
phenomenon.
We would like to thank Drs D. Cowan and J. Senn
of Sunnybrook Hospital of Toronto; Dr E. Gelfand
and the staff haematologists at the Hospital for Sick
Children, Toronto, and Dr J. Curtis and Dr R.
Hasselback of the Princess Margaret Hospital,
Toronto, for providing clinical materials and helpful
discussion during the course of these studies. This
work was supported by grants from the Ontario
Cancer Treatment and Research Foundation and the
National Cancer Institute of Canada.
REFERENCES
BALTIMORE, D., SILVERSTONE, A. E., KUNG, P. C.,
HARRISON, T. A. & MCCAFFREY, R. (1976) What
cells contain terminal deoxynucleotidyl trans-
ferase? In The Generation of Antibody Diver8ity: A
New Look. Ed. A. J. Cunningham. New York:
Academic Press. p. 21.
BERNSTEIN, A., MAK, T. W. & STEPHENSON, J. R.
(1977) The Friend virus genome: evidence for the
stable association of MuLV sequences and
sequences involved in erythroleukemic trans-
formation. Cell, 12, 287.
BHATTACHARYYA, J. R. (1975) Terminal deoxyribo-
nucleotidyl transferase in human leukemia.
Biochem. Biophy8. Res. Commun., 62, 367.
BOLLUM, F. J. (1978) Terminal deoxynucleotidyl
transferase biological studies. Adv. Enzymol., 47,
347.
COLEMAN, M. S., HUTTON, J. J., DE SIMONE, P. &
BOLLUM, F. J. (1974) Terminal deoxyribo-
nucleotidyl transferase in human leukemia. Proc.
Natl Acad. Sci. U.S.A., 71, 4404.
COLEMAN, M. S., GREENWOOD, M. F., HUTTON, J. J.,
BOLLUM, F. J., LAMPKIN, B. & HOLLAND, P. (1976)
Serial observations on terminal deoxynucleotidyl
transferase activity and lymphoblast surface
markers in acute lymphoblastic leukemia. Cancer
Res., 36, 120.
FAHEY, J. L. & TERRY, E. W. (1973) Ion exchange
chromatography and gel filtration. In Handbook
of Experimental Immunology. Ed. D. W. Weir.
Oxford: Blackwell. p. 7.
GREENWOOD, M. F., COLEMAN, M. S., HUTTON, J. J.
& 4 others (1977) Terminal deoxynucleotidyl-
transferase distribution in neoplastic and hemato-
poietic cells. J. Clin. Invest., 59, 889.
GREGOIRE, K. E., GOLDSCHNEIDER, I., BARTON,
R. W. & BOLLUM, F. J. (1977) Intracellular dis-
tribution of terminal deoxynucleotidyl trans-
ferase in rat bone marrow and thymus. Proc. Natl
Acad. Sci., U.S.A., 74, 3993.
HASSELBACK, R., CURTIS, J., SOOTS, M., ROBERTSON,
G. L., COWAN, D. H. & HART, G. D. (1967) The
influence of morphology on prognosis in acute
leukemia. Can. Med. Assoc. J., 94, 1610.
HOFFBRAND, A. V., GANESHAGURU, K., JANOSSY, G.,
GREAVES, M. F., CATOVSKY, D. & WOODRUFF,
R. K. (1977) Terminal deoxynucleotidyl-trans-
ferase levels and membrane phenotypes in diag-
nosis of acute leukaemia. Lancet, ii, 520.
HOFFBRAND, A. V., GANESHAGURU, K., JANOSSY,
G., GREAVES, M. F. & CATOVSKY, D. (1978)
Terminal transferase in acute leukaemia. Br. J.
Haematol., 36, 439.
HUTTON, J. J. & COLEMAN, M. S. (1976) Terminal
deoxynucleotidyl transferase measurements in
differential diagnosis of adult leukaemias. Br. J.
Haematol., 34, 447.TdT IN SINGLE LEUKAEMIC CELLS 167
KUNG, P. C., LONG, J. C., RATLIFF, R. L., HARRISON,
T. A. & BALTIMORE, D. (1978) Terminal deoxy-
nucleotidyl transferase in the diagnosis of
leukemia and malignant lymphoma. Am. J. Med.,
64, 788.
MARKS, S. M., BALTIMORE, D. & MCCAFFREY, R.
(1978) Terminal transferase as a predictor of
initial responsiveness to vincristine and prednisone
in blastic chronic myelogeneous leukemia. N.
Engl. J. Med., 298, 812.
MCCAFFREY, R., SMOLER, D. F. & BALTIMORE, D.
(1973) Terminal deoxynucleotidyl transferase in a
case of childhood acute lymphoblastic leukemia.
Proc. Natl Acad. Sci., U.S.A., 70, 521.
MCCAFFREY, R., HARRISON, T. A., PARKMAN, R. &
BALTIMORE, D. (1975) Terminal deoxynucleotidyl
transferase activity in human leukemic cells and
in normal human thymocytes. N. Engl. J. Med.,
292, 775.
OKAMURA, S., CRANE, F., MESSNER, H. A. & MAK,
T. W. (1978) Purification of terminal deoxy-
nucleotidyltransferase by oligonucleotide affinity
chromatography. J. Biol. Chem., 253, 3765.
SARIN, P. S., ANDERSON, P. N. & GALLO, R. C. (1976)
Terminal deoxynucleotidyl transferase activities
in human blood leukocytes and lymphoblast cell
lines: High levels in lymphoblast cell lines and in
blast cells of some patients with chronic myelo-
geneous leukemia in acute phase. Blood, 47, 11.
SRIVASTAVA, B. I. S., KHAN, S. A. & HENDERSON,
E. S. (1976) High terminal deoxynucleotidyl
transferase activity in acute myelogenous
leukemia. Cancer Res., 36, 3847.
STANWORTH, D. R. & TURNER, M. W. (1973)
Immunochemical analysis ofimmunoglobulins and
their subunits. In Handbook of Experimental
Immunology. Ed. D. W. Weir. Oxford: Blackwell.
p. 16.
SUGIMOTO, M. & BOLLUM, F. J. (1979) Terminal
deoxynucleotidyl transferase in chick embryo
lymphoid tissue. J. Immunol., 122, 393.
TAYLOR, J. M. & SCHIMKE, R. T. (1974) Specific
binding of albumin antibody to rat polysomes.
J. Biol. Chem., 219, 3597.